Thermo Fisher (TMO) announced that its board of directors has authorized the repurchase of $4B of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $1B was remaining.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Mainz Biomed, Thermo Fisher sign collaboration agreement
- Seer, Thermo Fisher enter co-marketing and sales agreement
- Thermo Fisher price target lowered to $718 from $767 at RBC Capital
- Thermo Fisher price target lowered to $620 from $625 at Bernstein
- Thermo Fisher price target lowered to $622 from $632 at Baird